⌘K

Home/Filings/4/0001576885-23-000052

4//SEC Filing

Ives Jeffrey L. 4

Accession 0001576885-23-000052

CIK 0001576885other

View on SEC.gov Company Profile

Filed

Aug 17, 8:00 PM ET

Accepted

Aug 18, 6:31 PM ET

Size

12.8 KB

Accession

0001576885-23-000052

Insider Transaction Report

Form 4

Period: 2023-08-17

Acumen Pharmaceuticals, Inc.ABOS

Ives Jeffrey L.

Director

Transactions

Sale
Common Stock
2023-08-17$6.66/sh−2,800$18,648→ 0 total
Exercise/Conversion
Common Stock
2023-08-17$0.72/sh+39,149$28,187→ 39,149 total
Exercise/Conversion
Common Stock
2023-08-17$1.19/sh+2,800$3,332→ 2,800 total
Exercise/Conversion
Stock Option (right to buy)
2023-08-17−39,149→ 0 total
Exercise: $0.72Exp: 2029-03-01→ Common Stock (39,149 underlying)
Sale
Common Stock
2023-08-17$6.48/sh−39,149$253,686→ 0 total
Exercise/Conversion
Stock Option (right to buy)
2023-08-17−2,800→ 0 total
Exercise: $1.19Exp: 2031-01-03→ Common Stock (2,800 underlying)

Footnotes (2)

[F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on May 17, 2023.
[F2]The option is fully vested.

Documents

1 file

4
wk-form4_1692397878.xmlPrimary
FORM 4

Issuer

Acumen Pharmaceuticals, Inc.

CIK 0001576885

Entity typeother

Related Parties

1

filerCIK 0001614096

Filing Metadata

Form type: 4
Filed: Aug 17, 8:00 PM ET
Accepted: Aug 18, 6:31 PM ET
Size: 12.8 KB

View on SEC.gov